State Street
IMRX icon

State Street’s Immuneering IMRX Stock Holding History

State Street’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5M Buy
1,001,995
+733,475
+273% +$3.71M ﹤0.01% 3010
2026
Q1 		$1.42M Sell
268,520
-2,133,718
-89% -$10.9M ﹤0.01% 3399
2025
Q4 		$15.8M Buy
2,402,238
+2,229,374
+1,290% +$14.3M ﹤0.01% 2388
2025
Q3 		$1.21M Buy
172,864
+75,529
+78% +$392K ﹤0.01% 3468
2025
Q2 		$328K Buy
97,335
+18,800
+24% +$32.2K ﹤0.01% 3711
2025
Q1 		$119K Hold
78,535
– – ﹤0.01% 3934
2024
Q4 		$173K Buy
78,535
+9,300
+13% +$19.3K ﹤0.01% 3883
2024
Q3 		$172K Hold
69,235
– – ﹤0.01% 3854
2024
Q2 		$88.6K Sell
69,235
-307,661
-82% -$506K ﹤0.01% 4042
2024
Q1 		$1.09M Buy
376,896
+3,234
+0.9% +$18.1K ﹤0.01% 3446
2023
Q4 		$2.75M Buy
373,662
+12,366
+3% +$82.4K ﹤0.01% 3201
2023
Q3 		$2.77M Buy
361,296
+27,674
+8% +$254K ﹤0.01% 3187
2023
Q2 		$3.38M Buy
333,622
+279,887
+521% +$2.69M ﹤0.01% 3183
2023
Q1 		$522K Sell
53,735
-300
-0.6% -$1.7K ﹤0.01% 3733
2022
Q4 		$262K Buy
54,035
+24,900
+85% +$221K ﹤0.01% 4008
2022
Q3 		$417K Buy
29,135
+4,100
+16% +$32.6K ﹤0.01% 3848
2022
Q2 		$135K Sell
25,035
-151,445
-86% -$808K ﹤0.01% 4376
2022
Q1 		$1.14M Buy
176,480
+56,539
+47% +$543K ﹤0.01% 3768
2021
Q4 		$1.94M Buy
119,941
+18,739
+19% +$456K ﹤0.01% 3645
2021
Q3 		$2.69M Buy
+101,202
New +$2.72M ﹤0.01% 3529

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

State Street's IMRX Position: Q2 2026 in Review

State Street increased its Immuneering (IMRX) stake by 273% in Q2 2026, buying an estimated $3.71M and bringing the position to 1,001,995 shares worth $5M. The position accounts for ﹤0.01% of the portfolio, ranked #3010.

State Street first reported a position in IMRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $15.8M in Q4 2025. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • State Street held 1,001,995 shares of Immuneering worth $5M as of Q2 2026.
  • State Street bought 733,475 Immuneering shares in Q2 2026, an estimated $3.71M.
  • Immuneering made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3010 holding.
  • State Street first reported a position in Immuneering in Q3 2021 and has held it in 20 quarters since.
  • State Street's Immuneering position peaked at $15.8M in Q4 2025.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.